We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Read MoreHide Full Article
Theravance Biopharma (TBPH - Free Report) shares rallied 7.6% in the last trading session to close at $9.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.7% gain over the past four weeks.
The company has developed Yupelri, a nebulized treatment for chronic obstructive pulmonary, disease in collaboration with Viatris. The company is also developing ampreloxetine in late-stage studies for symptomatic neurogenic orthostatic hypotension. The encouraging pipeline progress, along with the uptake of Yupelri, might have driven the share price rally.
This biopharmaceutical company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +20.8%. Revenues are expected to be $14.54 million, up 39.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Theravance Bio, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TBPH going forward to see if this recent jump can turn into more strength down the road.
Theravance Bio belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, ProPhase Labs, Inc. (PRPH - Free Report) , closed the last trading session 1.9% higher at $6.52. Over the past month, PRPH has returned 31.7%.
For ProPhase Labs, the consensus EPS estimate for the upcoming report has changed -100% over the past month to -$0.26. This represents a change of -966.7% from what the company reported a year ago. ProPhase Labs currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Theravance Biopharma (TBPH - Free Report) shares rallied 7.6% in the last trading session to close at $9.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.7% gain over the past four weeks.
The company has developed Yupelri, a nebulized treatment for chronic obstructive pulmonary, disease in collaboration with Viatris. The company is also developing ampreloxetine in late-stage studies for symptomatic neurogenic orthostatic hypotension. The encouraging pipeline progress, along with the uptake of Yupelri, might have driven the share price rally.
This biopharmaceutical company is expected to post quarterly loss of $0.19 per share in its upcoming report, which represents a year-over-year change of +20.8%. Revenues are expected to be $14.54 million, up 39.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Theravance Bio, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TBPH going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Theravance Bio belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, ProPhase Labs, Inc. (PRPH - Free Report) , closed the last trading session 1.9% higher at $6.52. Over the past month, PRPH has returned 31.7%.
For ProPhase Labs, the consensus EPS estimate for the upcoming report has changed -100% over the past month to -$0.26. This represents a change of -966.7% from what the company reported a year ago. ProPhase Labs currently has a Zacks Rank of #4 (Sell).